<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01466569</url>
  </required_header>
  <id_info>
    <org_study_id>AbGenomics-2010.007.01</org_study_id>
    <nct_id>NCT01466569</nct_id>
  </id_info>
  <brief_title>An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 A/B Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AbGn-7 Therapy Alone and in Combination With the FOLFOX7 Treatment Regimen in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbGenomics B.V Taiwan Branch</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbGenomics B.V Taiwan Branch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability profile including the&#xD;
      dose limiting toxicity of AbGn-7 in patients with chemo-refractory advanced solid tumor of&#xD;
      epithelial origin, and of AbGn-7 in combination with FOLFOX7 in patients with&#xD;
      chemo-naive/chemo-refractory recurrent, locally advanced or metastatic gastric cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Monoclonal antibodies, alone or in combination with chemotherapeutic agents, have been proven&#xD;
      to be effective treatment for many malignant diseases in human. Antibodies can mediate&#xD;
      cytotoxicity through complement dependent cytotoxicty (CDC), antibody dependent cell mediated&#xD;
      cytotoxicity (ADCC) or apoptosis.&#xD;
&#xD;
      AbGn-7 was identified based on its direct killing (apoptosis-inducing) activities towards&#xD;
      cancer cells expressing its epitope. In vitro data also demonstrated its ability to elicit&#xD;
      CDC and ADCC. The in vivo xenograft study of AbGn-7 demonstrated that AbGn-7 alone or in&#xD;
      combination with chemotherapeutic agents successfully suppressed the growth of gastric,&#xD;
      pancreatic, and colorectal tumours. The NHP study proved the safety profile of AbGn-7. The&#xD;
      present Phase 1 clinical study is designed to evaluate the safety and tolerability of AbGn-7&#xD;
      alone in patients with solid tumors of epithelial origin (Phase 1a) and in combination with a&#xD;
      current chemotherapeutic regimen FOLFOX7 in patients with recurrent, locally advanced or&#xD;
      metastatic gastric carcinoma (Phase 1b).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety will be assessed by analysis of adverse event, clinical laboratory tests and physical examination</measure>
    <time_frame>10 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics will be assessed at 3 different dose levels in phase 1a and at 2 dose levels in phase 1b</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum anti-drug antibodies will be assessed at 3 different dose levels in phase 1a and at 2 dose levels in phase 1b</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response rate by Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Solid Tumor of Epithelial Origin</condition>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>AbGn-7 phase 1a cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AbGn-7 phase 1a cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AbGn-7 phase 1a cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AbGn-7 phase 1b cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AbGn-7 phase 1b cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AbGn-7</intervention_name>
    <description>Phase 1a: dose escalation; Drug: AbGn-7 weekly iv infusion Duration: 6 weeks</description>
    <arm_group_label>AbGn-7 phase 1a cohort 1</arm_group_label>
    <arm_group_label>AbGn-7 phase 1a cohort 2</arm_group_label>
    <arm_group_label>AbGn-7 phase 1a cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AbGn-7</intervention_name>
    <description>Phase 1b: two doses (one dose below MTD/MAD and MTD/MAD as determined in phase 1a) Drug: AbGn-7 weekly iv infusion combined with FOLFOX7 Duration: 6 weeks</description>
    <arm_group_label>AbGn-7 phase 1b cohort 1</arm_group_label>
    <arm_group_label>AbGn-7 phase 1b cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. must provide written informed consent.&#xD;
&#xD;
          2. must be ≥18 years of age, either sex and of any race/ethnicity.&#xD;
&#xD;
          3. Phase 1a: must have a histologically or cytologically confirmed advanced malignant&#xD;
             solid tumor of epithelial origin and must have failed on previous chemotherapy. Phase&#xD;
             1b: must have a histologically or cytologically confirmed, recurrent, locally advanced&#xD;
             or metastatic gastric cancer with measurable disease; must be chemo-naïve or must have&#xD;
             failed on previous chemotherapy; must not have received an oxaliplatin-based&#xD;
             chemotherapeutic regimen or monoclonal antibody therapy.&#xD;
&#xD;
          4. must have an Eastern Cooperative Oncology Group Performance Status of ≤2.&#xD;
&#xD;
          5. must have adequate hematological, renal and liver functions within 3 weeks prior to&#xD;
             first study drug administration as evidenced by: a) Absolute neutrophil count ≥1.5 x&#xD;
             109/L, b) Hemoglobin ≥90 g/L (≥80 g/L for patients with documented renal cell&#xD;
             carcinoma), c) Platelet count ≥100 x 109/L, d) Serum creatinine ≤1.5 x upper limit of&#xD;
             normal ULN or a calculated creatinine clearance ≥60 mL/minute, e) Total bilirubin &lt;1.5&#xD;
             x ULN, except for patients with documented Gilbert's disease, f) AST/SGOT and ALT/SGPT&#xD;
             &lt; 2.5 x ULN, or, in the presence of documented liver metastases, ≤5 x ULN.&#xD;
&#xD;
          6. must be able to adhere to dose and visit schedules.&#xD;
&#xD;
          7. Each female patient of childbearing potential must agree to use a medically accepted&#xD;
             method of contraception or to abstain from sexual intercourse and each male patient&#xD;
             must agree to use a medically accepted method of contraception or to abstain from&#xD;
             sexual intercourse during the study and for 60 days after stopping the study drug.&#xD;
&#xD;
          8. A life expectancy of at least 3 months.&#xD;
&#xD;
          9. Available tumor tissue in the form of unstained slides for determination of AbGn-7&#xD;
             epitope expression (optional for Phase 1a, obligatory for Phase 1b). Patients without&#xD;
             archival/banked tumor tissue obtained at the time of initial diagnosis must have a&#xD;
             biopsy performed according to institutional guidelines prior to the initiation of&#xD;
             treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. No current treated or untreated leptomeningeal metastasis or a metastatic CNS lesion.&#xD;
&#xD;
          2. For Phase 1a, patients should not have received chemotherapy within 30 days prior to&#xD;
             initiation of AbGn-7 therapy. For Phase 1b, patients should not have received&#xD;
             oxaliplatin-based chemotherapy or monoclonal antibody therapy for their gastric cancer&#xD;
             prior to enrollment.&#xD;
&#xD;
          3. Have note received radiation therapy within 3 weeks prior to first study drug&#xD;
             administration and must have adequately recovered from any associated toxicity and/or&#xD;
             complications of this intervention.&#xD;
&#xD;
          4. Have not undergone major surgery within 3 weeks prior to the first study drug&#xD;
             administration and must have adequately recovered from the toxicity and/or&#xD;
             complications of these interventions.&#xD;
&#xD;
          5. No current human immunodeficiency virus (HIV) infection or a current HIV-related&#xD;
             malignancy.&#xD;
&#xD;
          6. No current active hepatitis B or C.&#xD;
&#xD;
          7. No any serious or uncontrolled infection.&#xD;
&#xD;
          8. No uncontrolled diabetes mellitus, defined as a HbA1c of ≥7.5% in a patient with&#xD;
             documented diabetes mellitus.&#xD;
&#xD;
          9. No any of the following within 6 months prior to first study drug administration:&#xD;
             myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery&#xD;
             bypass graft, symptomatic congestive heart failure, clinically significant cardiac&#xD;
             dysrhythmia or clinically significant ECG abnormality, cerebrovascular accident or&#xD;
             transient ischemic attack, or seizure disorder.&#xD;
&#xD;
         10. No persistent, unresolved NCI CTCAE Grade ≥2 drug-related toxicity associated with&#xD;
             previous chemotherapy.&#xD;
&#xD;
         11. Not participating in any other clinical study with a potentially therapeutic agent, or&#xD;
             have not received another investigational product within 21 days.&#xD;
&#xD;
         12. No any clinically significant condition or situation which would interfere with the&#xD;
             study evaluations or optimal participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shih-Yao Lin, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AbGenomics B.V Taiwan Branch</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Devalingham Mahalingam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center-CTRC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anthony Olaszanski, MD, RPh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kuen-Hui Yeh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruey-Kuen Hsieh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mackay Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Rockledge</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center-CTRC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MacKay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>November 2, 2011</study_first_submitted>
  <study_first_submitted_qc>November 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2011</study_first_posted>
  <last_update_submitted>June 22, 2015</last_update_submitted>
  <last_update_submitted_qc>June 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumor</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>Oncology</keyword>
  <keyword>monoclonal Antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

